Project Summary/Abstract
This R21 application for the NOSI: Bold New Bioengineering Research for Heart, Lung, Blood and Sleep
Disorders and Diseases details the technical development of a unique method to maintain whole human lungs
for an extended period in order to revolutionize solid organ transplantation and human translational research.
Normothermic ex situ, or ex vivo, organ perfusion (EVOP) is a clinically accepted method of preserving,
evaluating, and rehabilitating whole organs for transplantation. EVOP has also been utilized by scientists for
translational research and emerged as an important platform to study organs with fully intact cell-cell interactions,
endothelial and epithelial interfaces, and with the entire spectrum of cellular compartments seen in vivo.
Therefore, EVOP provides a unique platform to preserve organs for transplantation, as well as to study human
physiology and pathology through preclinical translational studies. Unfortunately, EVOP is currently severely
limited due to the short time frame of organ health stability currently provided by the technology. Therefore,
there is an unmet need in EVOP strategies that requires new technology. The investigative team has the
needed experience in organ transplantation, pulmonary physiology, biomedical engineering and vascular biology
in order to ensure success of the proposed work. Aim 1 will leverage the expertise of the investigators with a
porcine model of lung EVOP to extended stable organ preservation to at least 5 days through several key
technology advances, including metabolic substrate support, waste product removal, dual perfusion, and the use
of cellular enriched perfusate. Porcine lungs were utilized extensively for the initial development of lung EVOP
and provide a high-fidelity model for translational work. In Year 2, Aim 2 will leverage and validate lessons
learned during Aim 1 using human lungs from consented organ donors. The overall objective of this proposal
is to obviate the current limitation of time for lung EVOP by adapting existing ex vivo lung perfusion
strategies to allow for perpetual organ preservation and rehabilitation, or POPR. POPR would radically
change allocation and availability of organs, allow time for interventions that could rehabilitate otherwise
unusable organs, improve organs via immunomodulation or microbiologic clearance, and potentially mitigate
other factors that limit the use of potential organ donors. Therefore, the development of POPR would be of
tremendous public health importance and our proposal leverages the transdisciplinary expertise of lung
transplantation, organ preservation, vascular endothelial health and biomedical engineering specialists. The
technology proposed herein, once developed, could be used by transplant programs clinically and by
researchers in specialized centers across the country. Importantly, principals developed herein can be applied
to other solid organs, including heart, kidney, and small bowel, to extend solid organ transplantation and
research.